sequentially versus Ray. XXXX call. quarter in the expectations performed flat you, quarter with top exceeding line the guidance. the of third and our thanks joining end and Novanta EPS morning for with revenue Good everybody our Thank in our second of
representing year-over-year a X% decline X% on and revenue, basis, below in grew on million reported $XXX a a delivered both just on an organic basis. year-over-year, our organic decline company X% basis. revenue a Year-to-date, reported Our and
exceeded top guidance share of at earnings We X.XX adjusted bookings million, by was adjusted was XX% our the $XX versus quarter. book-to-bill end second the quarter, our per the grew EBITDA $X.XX, in sequentially and
Our medical revenue with team favorable in our executed deteriorating very of over are Novanta's industrial well markets spending positioning in capital a half growing. that climate. structurally is
growing diverse motion, faster capabilities market and vision applications, precision trends. in proprietary productivity medicine, secular driven Industry photonics We the remain than with X.X, on healthcare and a laser-focused set of by
to secular We such invasive are and minimally and automation and strongly applications and our precision robotics. proprietary through DNA surgery, growth position business growth enhance innovation sustainable commercial surgery, capabilities investing potential in in cycles advanced robotic as sequencing, long-term technology processing, material
In to solid introduce to the to success efforts third and quarter, continued customers. our in our innovations see momentum new we
decade. we investments our pipeline strongest our innovation the of the On a -- back is innovation in made, innovations in feel
result, to committed we these are the bring continue market to R&D to innovations a of As half to in XXXX. and second XXXX in invest
of labor in results. continue fruits our see We today's to also the
year-to-date year-over-year. New product grew revenue XX%
digit be from four revenue to index, new ago. sales years a Our continue year-to-date of in XX% vitality percentages which is last mid-single launched the years, few products versus
pipeline. our customer growth, performance the All-in-all, of quarter. design with We're opportunity platforms the year-over-year third seeing proud wins over strong accelerated on team many on the design of I'm quarter teams to the as third win XX% to our openings executed, by strong gain funnel of share the Our strong opportunities. back in our innovation
oversee leaders our implementation This pipeline. and strongest testament In chain system, -- to business to of is supply one internal appointment Novanta our our and in efforts. appointed accelerate quarter, we our an growing of talent a have and the the growth operators corporate
Novanta vigorously applied is operating and the long-term The growth working to across and with gross Novanta entire performance margin customer a common enterprise sustained accelerate processes focus system and a drive of set optimization. tools satisfaction, on growth of common and inventory initial expansion, way
footprint feel consolidation, harmonize as value such performance, rationalization, with appointment more our An continuous important element pricing. this centers We be in and improvement, chain capital efforts in deployment able orchestrate manufacturing that supply is supplier areas we to will end-to-end competence our swiftly and strategy M&A. and
dramatically such third as high applications. Arges accelerates the Arges. micromachining, this additive our acquisition our scanning year quarter, In strategy laser and manufacturing, we intelligent And subsystem into third closed markets growth medical
beam The our synergies IP laser macro photonic We channels. of in steering the engineering business proprietary doubles is strong segment. adds these our breadth by phenomenal sales our Novanta capabilities and and And while of Photonics technology and of knowhow exceeded a see industrial to applying sales and greatly have engineering Arges expectations. capabilities headwinds, term through capabilities affected the Arges short base project acquisition
strategic accelerates able opportunity we products innovation at market in we we and the perspective, we the an will right if hitting remain As it returns, our pipeline move to way in and M&A feel arises first our we look pipeline with an strategy. a accelerate will very quickly disciplined be fit now, very that XXXX. meaningful on From
we're seeing touch climate. what me in let our Now, the markets in macroeconomic on overall
that double-digit in third continue markets businesses very medical the XXXX. We for mid-teens of in growth to expect medical the and full our Our year to be continue quarter see momentum robust.
and these minimally Novanta that momentum driven and momentum innovations expect Momentum is surgery. by markets, share to these broad-based, areas. but continue in pleased the in we are invasive gaining is robotic particularly with in
double-digit also climate. to growth in XXXX in expect uncertain our year-over-year sequencing. our our we're double-digit medical of would our revenue, point achieving in XX% as out, business like businesses a an over Representing to despite medical growth I serve DNA decline in we macroeconomic engine
the the we indices since spending have industrial capital further consistent in climate momentum lowest in deterioration PMI quarter decelerating seen most third further geographies. XXXX a saw the We in for with
we This macro our is actually market. this to our continued share on a advanced environment environment. last in we're industrial uncertainty The phenomenon earnings gaining as purely in tough cost reported in call softening
And with although the sequentially in with in bottoming we've states came sequential growing business mostly for a bookings request improvement quarter bookings, which in We are quarter. expect late XX%, by out modest of seen some our only these the fourth XXXX. now
the Asia-Pacific customer the with and the were trade particularly in wars felt and Geographically, resulting region, Europe. China, uncertainty
China Our We're markets seeing the infrastructure bottoming market XG out processing cloud-based and of and to Photonics quarter a rapidly the year-to-date, industrial by in demand our China, decline signs in by segment. growing driven material in deteriorated microelectronics revenue XX% XX% quarter, and driven to investments. in for declines
about year-over-year modest relatively are As a in microelectronics level comparisons. revenue, meaningful while have an to Novanta declines XX% contributions overall our China the of reminder, for impact enough are at at
very Our is Europe, our where XX% teams business well performing are up in year-to-date.
well year. was revenue felt here down quarter deceleration However, with versus the as third prior low-single digits
costs decisively our the areas, we're we're see our do temporary, trimming expand While still growth through cycle. as innovation investments technology and this weak we to not manufacturing and in proprietary weakness in positions on conviction business of wavering
the and decade share feel we in the cycle. through As strongest an a we mentioned seeing to opportunity have lineup innovation before, gain
the story our year. the absolute momentum segments. me this carrying which with into of Starting turn strong rest again operating Now, to quarter segment, with Vision let the growth was the
segment a the predominantly diagnostics, in devices. market. the minimally reminder, surgery, As a and serves medical invasive Large Vision vitro medical application other includes,
product new year-to-date. and For year, growth. continued revenue total year-to-date XX% revenue the sales products to third driven the be delivered new Growth and last quarter, new XX% solid revenue a by maintained of about Vision In allowances very new segment our product customers. over XX% at versus segment, grew year-over-year of Vision product
launch X.XX. to well medical Vision momentum, we through as market was book-to-bill predominantly as segment The our momentum, and mentioned, the new market segment we which as we expect progress in as see Vision continue XXXX. The previously solid serves product
insufflator did team job keeping depth new superb performed the a MIS for XXXX, with the last momentum continuing quarters. their the up well We and FMXXX in third of couldn't integrated evacuation. innovation's of with The Our of from in one strengths more customer product with business innovations, tremendous a its relationship be the this few pleased business. demand extremely the quarter one smoke
filtering Our into functionality insufflator insufflator, requiring not product a and integrates workflow, and evacuation separate optimizing the FMXXX innovation box. smoke evacuation smoke
been approximately pending smoke Worldwide or smoke US, required if have laws byproduct, all passed procedures. energy-based vaporization devise, a devices surgical surgical and is of tissue the in XX% of the evacuation a dangerous with during
opportunity. to uniquely positioned this is Our capitalize of market WOM business
lineup Moving on, attractive NDS to a our business. strong Med with integrated are exposure for now more we the X of a the with Change product addition significant NDS through XXXX. has segment very OR pleased
is it the NDS into quarter, in its manufacturing substantially our the the continue expected production complete center to and business transfer product MIS scale improving In to profitability, and efficiency. component improve fourth addition,
business show revenue. the quarter its to double-digit Analysis solid offerings. & product around machine growth machine Detection of continue In our momentum RFID of the see grade strong in product XXXX, launches continued medical third vision and to business RFID Finally, vision new
Motion declines industrial in the semiconductors, declined momentum Our quarter revenue in third in segment Precision XX% microelectronics, not where year-over-year markets. could and offset surgery robotic fantastic growth
XXXX. We to comps feel against in declines late is certain revenue second led are challenges a as these timing quarter, in there temporary, a which result, stopped and the order tough
seeing for sequentially third cloud-based bookings bill We're The to by improve. the in uptick infrastructure improving with seeing an basis. on quarter Precision book X.XX improved organic XG orders demand and the first signs the of investment, are recovery, giving XX% in and Motion to
and with and such dynamics We growth automation, markets. markets position continue dynamic robotics, serving structural to vehicles, technology surgery in our as robotic precise motion like multiple precision control metrology, unmanned
us acquisition our motion also solutions that control earlier critical We're Ingenia to customers. the control capability a which offer excited to year, intelligent now this adds allows about motion
of with motors GaN, ultra-small factor product lower, wires, based This and just weight. first and the which launched, an enables less allows demotion family unique was is technology, controls, integration footprint with or weight precision on fewer which and The gallium average, size. for of close magnitude encoders reducing order nitride our the form
robotics, We as surgical unmanned believe this applications. and vehicle is in particularly precision well critical as
are Within new year XX% grew the year-to-date, design versus market teams. last segment, commercial as and and wins bring revenue our than our expanding product more XX% Precision innovations new grew to we Motion
And call. as of dynamics performance the in reported ended due third down segment, capital the XX%, declined expected, earnings indicated last in Laser to driven spending earnings sequencing, year-over-year industrial revenue climate. the to rightly Turning few revenue Laser the Quantum double-digit by Quantum in DNA our in quarter Photonics have last as calls, we deteriorating was our on
clinical into short-term our business this positive of excitement as our with horizon. long-term very of our competitive a believe the temporary is applications still we nor this and sequencing growth about DNA lumpiness position early up in stages prospects demand long-term penetration market We on and numerous reiterate catalysts correlated the is
sensitive of our discussed, the The business impacted spending capital the we markets and and industrial also headwinds Photonics Synrad segment is which particularly performance too. was by deteriorating just macroeconomic that
indicated this stabilization on quarter third As our in versus last fourth bookings the second was the sequentially XX% our growth third as drag in expected quarter. quarter grew by in with the quarter more call, a
team XX% a the to close XX% Our Design the bookings environment. doing in Photonics versus photonics grew quarter, is the in wins by tough and job quarter. sequentially was the gaining third third second year-over-year X.XX share in quarter, in fantastic book-to-bill accelerated grew and
improve sequentially revenue fourth organic on Photonics quarter the to an expect in basis. growth We in
agility proud of positioning and we're performance weak medical our the with teams spending of pleased and in environment. capital our wrap-up, very in To and a business performance industrial our
is Our innovation new pipelines ever and design accelerating, and have they our bookings as been. product are introductions activity recovering, strong as win
for profitable in showing with Novanta's very stabilization. of to approach Novanta disciplined some providing the growth. medical well positioned is advanced across signs feel diversified leadership sustainable M&A, solid is markets, a foundation an combined environment, and is uncertain which We industrial position our macroeconomic long-term
the focused we markets strategy cycle. of technology investments Therefore, to to growing on positions conviction expand in medical and our business expand in through innovation wavering our proprietary not remain our
call the to details Robert So, provide that, turn over financial more our performance. Robert? I on will with to
